Generics North America (NAFTA) Industry Guide 2019-2028

You are here: Home Catalog Pharma & Healthcare Generic Drugs Country Overview (Pharma & Healthcare)

Generics North America (NAFTA) Industry Guide 2019-2028

Market Research Report Summary

Generics North America (NAFTA) Industry Guide 2019-2028 report is published on December 20, 2024 and has 220 pages in it. This 91制片厂 report provides information about Generic Drugs, Country Overview (Pharma & Healthcare), Pharma & Healthcare industry. It covers North America market data and forecasts. It is priced starting at USD 795.00 for Single User License (PDF) which allows one person to use this report.

Please read the description and table of contents of this research report given below to check whether it meets your research requirements. If not, then please do not hesitate to contact us using "Report Enquiry" form given below. We can customize this research report or suggest a new fully customized 91制片厂 report to meet your research goals and data requirements.

Generics North America (NAFTA) Industry Guide 2019-2028

Printer version

Send by email

Publication ID:听

MLI11240477

Publication Date:听

December 20, 2024

笔补驳别蝉:听

220

笔耻产濒颈蝉丑别谤:听

MarketLine

颁辞耻苍迟谤颈别蝉:听

North America

USD 795.00

Pay By Invoice

If you wish to purchase this report using bank/wire transfer against an invoice, please fill your details using request invoice form given below.

Globally Trusted Brand

We help executives from firms听to Start-ups听with their 91制片厂 needs thus听we can help you too.听

Secure Checkout

You can shop confidently as your online payments are processed using PCI DSS compliant secure payment gateways on our website.

Frequently Asked Questions

If you have any pre-sales听questions related to this report please let us know using the "Report Enquiry" form below. This will help us provide you听with answers听so that you can purchase with confidence. If you wish to read about frequently asked questions by our customers please visit our .

Tabs

Description

Generics North America (NAFTA) Industry Guide 2019-2028

Summary

The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of $88,125.3 million in 2023.The Canada was the fastest growing country, with a CAGR of 7% over the 2019-23 period.
- Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of $74,229.0 million in 2023. This was followed by Canada and Mexico, with a value of $7,717.8 and $6,178.6 million, respectively.
- The US is expected to lead the generics industry in the NAFTA bloc, with a value of $98,531.3 million in 2028, followed by Canada and Mexico with expected values of $10,446.0 and $7,720.0 million, respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market
- Leading company profiles reveal details of key generics market players鈥� NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country

Reasons to Buy

- What was the size of the NAFTA generics market by value in 2023?
- What will be the size of the NAFTA generics market in 2028?
- What factors are affecting the strength of competition in the NAFTA generics market?
- How has the market performed over the last five years?
- How large is the NAFTA generics market in relation to its regional counterparts?

Table of Contents

Table of Contents
1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA Generics
2.1. Industry Outlook
3 Generics in Canada
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
4 Macroeconomic Indicators
4.1. Country data
5 Generics in Mexico
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
6 Macroeconomic Indicators
6.1. Country data
7 Generics in The United States
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
8 Macroeconomic Indicators
8.1. Country data
9 Company Profiles
9.1. Teva Pharmaceutical Industries Ltd
9.2. Viatris Inc
9.3. Sun Pharmaceutical Industries Ltd
9.4. Novartis AG
9.5. Sandoz Group AG
9.6. Hikma Pharmaceuticals Plc
9.7. Sanofi
9.8. Les Laboratoires Servier SAS
9.9. Stada Arzneimittel AG
9.10. Bayer AG
9.11. Lupin Ltd
9.12. Aspen Pharmacare Holdings Ltd
9.13. EMS SA
9.14. Eurofarma Laboratorios SA
9.15. Ache Laboratorios Farmaceuticos SA
9.16. Apotex Inc
9.17. Teva Canada Ltd
9.18. Sandoz Canada Inc
9.19. CSPC Pharmaceutical Group Ltd
9.20. Sino Biopharmaceutical Ltd
9.21. Hansoh Pharmaceutical Group Co Ltd
9.22. Dr. Reddy's Laboratories Ltd
9.23. Cipla Ltd
9.24. Aurobindo Pharma Ltd
9.25. PT Kalbe Farma Tbk
9.26. PT Indofarma Tbk
9.27. PT Sanbe Farma
9.28. PT Soho Global Health Tbk
9.29. Friulchem SpA
9.30. DOC Generici SRL
9.31. Recordati SpA
9.32. Daiichi Sankyo Co Ltd
9.33. Towa Pharmaceutical Co Ltd
9.34. Sawai Group Holdings Co Ltd
9.35. Toho Holdings Co Ltd
9.36. Laboratorios Silanes SA de CV
9.37. Pfizer Inc
9.38. Biocad
9.39. R-Pharm
9.40. Pharmstandard
9.41. AstraZeneca Plc
9.42. Bluefish Pharmaceuticals AB
9.43. Navamedic ASA
9.44. Novartis International AG
9.45. Beacons Pharmaceuticals Pte Ltd
9.46. Abbott Laboratories SA
9.47. Adcock Ingram Holdings Ltd
9.48. Dongkook Pharmaceutical Co Ltd
9.49. JW Holdings Corp
9.50. Hanmi Pharmaceuticals Co Ltd
9.51. Dong Wha Pharma Co Ltd
9.52. Esteve Pharmaceuticals SA
9.53. Abdi Ibrahim Ilac Sanayi ve Ticaret AS
9.54. Deva Holding AS
9.55. Sandoz Inc
10 Appendix
10.1. Methodology
10.2. About MarketLine

List of Tables
List of Tables
Table 1: NAFTA countries generics industry, revenue ($m), 2019-28
Table 2: NAFTA countries generics industry, revenue ($m), 2019-23
Table 3: NAFTA countries generics industry forecast, revenue ($m), 2023-28
Table 4: Canada generics market value: $ million, 2018-23
Table 5: Canada generics market volume: % of total pharma volume, 2018-23
Table 6: Canada generics market geography segmentation: $ million, 2023
Table 7: Canada generics market value forecast: $ million, 2023-28
Table 8: Canada generics market volume forecast: % of total pharma volume, 2023-28
Table 9: Canada Size of Population (million), 2019-23
Table 10: Canada real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 11: Canada GDP (Current Prices, $ Billion), 2019-23
Table 12: Canada Inflation, 2019-23
Table 13: Canada Consumer Price Index (Absolute), 2019-23
Table 14: Canada exchange rate, 2018-23
Table 15: Mexico generics market value: $ million, 2018-23
Table 16: Mexico generics market volume: % of total pharma volume, 2018-23
Table 17: Mexico generics market geography segmentation: $ million, 2023
Table 18: Mexico generics market value forecast: $ million, 2023-28
Table 19: Mexico generics market volume forecast: % of total pharma volume, 2023-28
Table 20: Mexico Size of Population (million), 2019-23
Table 21: Mexico real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 22: Mexico GDP (Current Prices, $ Billion), 2019-23
Table 23: Mexico Inflation, 2019-23
Table 24: Mexico Consumer Price Index (Absolute), 2019-23
Table 25: Mexico exchange rate, 2018-23
Table 26: United States generics market value: $ million, 2018-23
Table 27: United States generics market volume: % of total pharma volume, 2018-23
Table 28: United States generics market geography segmentation: $ million, 2023
Table 29: United States generics market value forecast: $ million, 2023-28
Table 30: United States generics market volume forecast: % of total pharma volume, 2023-28
Table 31: United States Size of Population (million), 2019-23
Table 32: United States real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 33: United States GDP (Current Prices, $ Billion), 2019-23
Table 34: United States Inflation, 2019-23
Table 35: United States Consumer Price Index (Absolute), 2019-23
Table 36: United States exchange rate, 2018-23
Table 37: Teva Pharmaceutical Industries Ltd: key facts
Table 38: Teva Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 39: Teva Pharmaceutical Industries Ltd: Key Employees
Table 40: Viatris Inc: key facts
Table 41: Viatris Inc: Annual Financial Ratios
Table 42: Viatris Inc: Key Employees
Table 43: Sun Pharmaceutical Industries Ltd: key facts
Table 44: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 45: Sun Pharmaceutical Industries Ltd: Key Employees
Table 46: Novartis AG: key facts
Table 47: Novartis AG: Annual Financial Ratios
Table 48: Novartis AG: Key Employees
Table 49: Sandoz Group AG: key facts
Table 50: Sandoz Group AG: Key Employees
Table 51: Hikma Pharmaceuticals Plc: key facts
Table 52: Hikma Pharmaceuticals Plc: Annual Financial Ratios
Table 53: Hikma Pharmaceuticals Plc: Key Employees
Table 54: Sanofi: key facts
Table 55: Sanofi: Annual Financial Ratios
Table 56: Sanofi: Key Employees
Table 57: Les Laboratoires Servier SAS: key facts
Table 58: Les Laboratoires Servier SAS: Key Employees
Table 59: Stada Arzneimittel AG: key facts
Table 60: Stada Arzneimittel AG: Key Employees
Table 61: Bayer AG: key facts
Table 62: Bayer AG: Annual Financial Ratios
Table 63: Bayer AG: Key Employees
Table 64: Bayer AG: Key Employees Continued
Table 65: Bayer AG: Key Employees Continued
Table 66: Lupin Ltd: key facts
Table 67: Lupin Ltd: Annual Financial Ratios
Table 68: Lupin Ltd: Key Employees
Table 69: Aspen Pharmacare Holdings Ltd: key facts
Table 70: Aspen Pharmacare Holdings Ltd: Annual Financial Ratios
Table 71: Aspen Pharmacare Holdings Ltd: Key Employees
Table 72: EMS SA: key facts
Table 73: EMS SA: Key Employees
Table 74: Eurofarma Laboratorios SA: key facts
Table 75: Eurofarma Laboratorios SA: Key Employees
Table 76: Ache Laboratorios Farmaceuticos SA: key facts
Table 77: Ache Laboratorios Farmaceuticos SA: Key Employees
Table 78: Apotex Inc: key facts
Table 79: Apotex Inc: Key Employees
Table 80: Teva Canada Ltd: key facts
Table 81: Teva Canada Ltd: Key Employees
Table 82: Sandoz Canada Inc: key facts
Table 83: Sandoz Canada Inc: Key Employees
Table 84: CSPC Pharmaceutical Group Ltd: key facts
Table 85: CSPC Pharmaceutical Group Ltd: Annual Financial Ratios
Table 86: CSPC Pharmaceutical Group Ltd: Key Employees
Table 87: Sino Biopharmaceutical Ltd: key facts
Table 88: Sino Biopharmaceutical Ltd: Annual Financial Ratios
Table 89: Sino Biopharmaceutical Ltd: Key Employees
Table 90: Hansoh Pharmaceutical Group Co Ltd: key facts
Table 91: Hansoh Pharmaceutical Group Co Ltd: Annual Financial Ratios
Table 92: Dr. Reddy's Laboratories Ltd: key facts
Table 93: Dr. Reddy's Laboratories Ltd: Annual Financial Ratios
Table 94: Dr. Reddy's Laboratories Ltd: Key Employees

List of Figures
List of Figures
Figure 1: NAFTA countries generics industry, revenue ($m), 2019-28
Figure 2: NAFTA countries generics industry, revenue ($m), 2019-23
Figure 3: NAFTA countries generics industry forecast, revenue ($m), 2023-28
Figure 4: Canada generics market value: $ million, 2018-23
Figure 5: Canada generics market volume: % of total pharma volume, 2018-23
Figure 6: Canada generics market geography segmentation: % share, by value, 2023
Figure 7: Canada generics market value forecast: $ million, 2023-28
Figure 8: Canada generics market volume forecast: % of total pharma volume, 2023-28
Figure 9: Forces driving competition in the generics market in Canada, 2023
Figure 10: Drivers of buyer power in the generics market in Canada, 2023
Figure 11: Drivers of supplier power in the generics market in Canada, 2023
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Canada, 2023
Figure 13: Factors influencing the threat of substitutes in the generics market in Canada, 2023
Figure 14: Drivers of degree of rivalry in the generics market in Canada, 2023
Figure 15: Mexico generics market value: $ million, 2018-23
Figure 16: Mexico generics market volume: % of total pharma volume, 2018-23
Figure 17: Mexico generics market geography segmentation: % share, by value, 2023
Figure 18: Mexico generics market value forecast: $ million, 2023-28
Figure 19: Mexico generics market volume forecast: % of total pharma volume, 2023-28
Figure 20: Forces driving competition in the generics market in Mexico, 2023
Figure 21: Drivers of buyer power in the generics market in Mexico, 2023
Figure 22: Drivers of supplier power in the generics market in Mexico, 2023
Figure 23: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2023
Figure 24: Factors influencing the threat of substitutes in the generics market in Mexico, 2023
Figure 25: Drivers of degree of rivalry in the generics market in Mexico, 2023
Figure 26: United States generics market value: $ million, 2018-23
Figure 27: United States generics market volume: % of total pharma volume, 2018-23
Figure 28: United States generics market geography segmentation: % share, by value, 2023
Figure 29: United States generics market value forecast: $ million, 2023-28
Figure 30: United States generics market volume forecast: % of total pharma volume, 2023-28
Figure 31: Forces driving competition in the generics market in the United States, 2023
Figure 32: Drivers of buyer power in the generics market in the United States, 2023
Figure 33: Drivers of supplier power in the generics market in the United States, 2023
Figure 34: Factors influencing the likelihood of new entrants in the generics market in the United States, 2023
Figure 35: Factors influencing the threat of substitutes in the generics market in the United States, 2023
Figure 36: Drivers of degree of rivalry in the generics market in the United States, 2023

Companies Covered

Abbott Laboratories SA
Abdi Ibrahim Ilac Sanayi ve Ticaret AS
Ache Laboratorios Farmaceuticos SA
Adcock Ingram Holdings Ltd
Apotex Inc
Aspen Pharmacare Holdings Ltd
AstraZeneca Plc
Aurobindo Pharma Ltd
Bayer AG
Beacons Pharmaceuticals Pte Ltd
Biocad
Bluefish Pharmaceuticals AB
Cipla Ltd
CSPC Pharmaceutical Group Ltd
Daiichi Sankyo Co Ltd
Deva Holding AS
DOC Generici SRL
Dong Wha Pharma Co Ltd
Dongkook Pharmaceutical Co Ltd
Dr. Reddy's Laboratories Ltd
EMS SA
Esteve Pharmaceuticals SA
Eurofarma Laboratorios SA
Friulchem SpA
Hanmi Pharmaceuticals Co Ltd
Hansoh Pharmaceutical Group Co Ltd
Hikma Pharmaceuticals Plc
JW Holdings Corp
Laboratorios Silanes SA de CV
Les Laboratoires Servier SAS
Lupin Ltd
Navamedic ASA
Novartis AG
Novartis International AG
Pfizer Inc
Pharmstandard
PT Indofarma Tbk
PT Kalbe Farma Tbk
PT Sanbe Farma
PT Soho Global Health Tbk
Recordati SpA
R-Pharm
Sandoz Canada Inc
Sandoz Group AG
Sandoz Inc
Sanofi
Sawai Group Holdings Co Ltd
Sino Biopharmaceutical Ltd
Stada Arzneimittel AG
Sun Pharmaceutical Industries Ltd
Teva Canada Ltd
Teva Pharmaceutical Industries Ltd
Toho Holdings Co Ltd
Towa Pharmaceutical Co Ltd
Viatris Inc

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Enquiry / Request Invoice

Report Inquiry

Do you have more questions related to this 91制片厂 report after going through the description and table of contents?

We are here to help. Please use the form given below to let us know your questions related to this report.

Kindly use your official email address and contact number to ensure speedy response.

First Name *

Last Name *

Company *

Email Address *

Phone (Including International Code) *

Report Title *

Do you need invoice for purchasing this report? *

Address 1

Address 2

City/Town

Postal/Zip Code

Country

License Type

Your Inquiry *

CAPTCHA

This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Generic Drugs

Country Overview (Pharma & Healthcare)

Pharma & Healthcare

*Please note that the report cover image shown above is for representation purpose only. Actual report cover may vary.

听

Related Market Research Reports

Publication	Price
Generics BRIC (Brazil, Russia, India, China) Industry Guide 2019-2028 Generics BRIC (Brazil, Russia, India, China) Industry Guide 2019-2028 Summary The BRIC Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Key Highlights - Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the generics industry and had a total market value of $1,68,484.5 million in 2023. Russia was the fastest growing country with a CAGR of 16.2% over the 2019-23 period. - Within the generics industry, China is the leading country among the BRIC nations with market revenues of $1,21,016.7 million in 2023. This was followed by India, Russia and Brazil with a value of $22,824.0, $15,429.5, and $9,214.4 million, respectively. - China is...Read more	USD 995.00
Generics Top 5 Emerging Markets Industry Guide 2019-2028 Generics Top 5 Emerging Markets Industry Guide 2019-2028 Summary The Emerging 5 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Key Highlights - These countries contributed $1,61,156.7 million to the global generics industry in 2023, with a compound annual growth rate (CAGR) of 12.1% between 2007 and 2011. The top 5 emerging countries are expected to reach a value of $2,33,053.5 million in 2028, with a CAGR of 7.7% over the 2023-28 period. - Within the generics industry, China is the leading country among the top 5 emerging nations, with market revenues of $1,21,016.7 million in 2023. This was followed by India and Brazil with a value of $22,824.0 and $9,214.4 million, respectively. -...Read more	USD 995.00
Generics Global Industry Guide 2019-2028 Generics Global Industry Guide 2019-2028 Summary Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Key Highlights - A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus,...Read more	USD 1,495.00
Generics Global Industry Almanac 2019-2028 Generics Global Industry Almanac 2019-2028 Summary Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Key Highlights - A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus...Read more	USD 2,995.00
Generics Global Group of Eight (G8) Industry Guide 2019-2028 Generics Global Group of Eight (G8) Industry Guide 2019-2028 Summary The G8 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Key Highlights - The G8 countries contributed $1,61,715.9 million in 2023 to the global generics industry, with a compound annual growth rate (CAGR) of 5.8% between 2019 and 2023. The G8 countries are expected to reach a value of $2,15,698.2 million in 2028, with a CAGR of 5.9% over the 2023-28 period. - Among the G8 nations, the US is the leading country in the generics industry, with market revenues of $74,229.0 million in 2023. This was followed by Germany and the UK, with a value of $27,662.3 and $15,516.9 million, respectively. - The US is expected to lead...Read more	USD 1,495.00

Clients Who Trust Us

Need tailor made 91制片厂 solution? We can help you with that too.

Contact Us

About Us

At 91制片厂. we aim to make it easier for decision makers to find relevant information and locate right 91制片厂 reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global 91制片厂 firms who are known leaders in their respective domains to obtain right 91制片厂 solution for our customer鈥檚 needs, be it custom research or syndicated research reports.

Contact Us

91制片厂
16192 Coastal Hwy
Lewes, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

Latest Blog Posts

Stay Connected

Disclaimer: 91制片厂. has no affiliation to, and is not associated with any other website(s) or organization(s). We offer syndicated research reports (like country analysis, SWOT analysis, competitive intelligence, industry reports, company reports and market analysis & trends reports) and custom 91制片厂 from our website MarketResearchReports.com only.

If you are looking for a 91制片厂 solution for your research requirements, please begin your search using the search box on top of this page or use our chat system to speak to our 91制片厂 consultants or directly write to us.

91制片厂